← Back to Search

Unknown

BMS-986369, Part 1 dose escalation for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug called BMS-986369 in healthy adults to see if it's safe, well-tolerated, and how much of it gets into the bloodstream. It also looks at how a high-fat meal affects the drug's absorption.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: BMS-986369, Part 1 dose escalationExperimental Treatment1 Intervention
Group II: BMS-986369 under fed conditions, Part 2 Food effectExperimental Treatment1 Intervention
Group III: BMS-986369 under fasted conditions, Part 2 Food effectExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986369
2022
Completed Phase 1
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,688 Previous Clinical Trials
4,096,739 Total Patients Enrolled
~21 spots leftby Dec 2025